Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA approves injectable nanobody gefurulimab for myasthenia gravis
00

FDA approves injectable nanobody gefurulimab for myasthenia gravis

Nov 13, 2026

The FDA has approved AstraZeneca and Alexion's gefurulimab (Klygefa), a once-weekly self-administered injectable nanobody targeting complement component 5 (C5) for adults with anti-AChR antibody-positive generalized myasthenia gravis. Approval follows the phase III PREVAIL trial involving 260 adults, which demonstrated significant functional improvements on the MG-ADL scale through 52 weeks. Gefurulimab joins competing C5 inhibitors eculizumab, ravulizumab, and zilucoplan, and carries a boxed warning for life-threatening Neisseria meningitidis infections managed under a REMS program requiring meningococcal vaccination compliance.

Gefurulimab FDA approval

  • ▪In September 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended gefurulimab for approval in the European Union
  • ▪The FDA approved once-weekly self-administered injectable gefurulimab (Klygefa) to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
  • ▪Gefurulimab is a dual-binding nanobody that blocks complement component 5 (C5) activation and binds to serum albumin to provide an extended half-life for once-weekly dosing

PREVAIL trial results

  • ▪The phase III PREVAIL trial met its primary endpoint, demonstrating a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scale scores versus placebo at week 28 with a treatment difference of -1.6 points
  • ▪Most treatment-emergent adverse events in the PREVAIL trial were mild to moderate, with injection site reactions (9.9%), headache (9.9%), and back pain (7.6%) being the most common among gefurulimab recipients
  • ▪The phase III PREVAIL trial randomized 260 adults with anti-AChR antibody-positive generalized myasthenia gravis to evaluate weekly subcutaneous gefurulimab against placebo over 26 weeks

C5 inhibitor competitors

  • ▪Editorial authors Christiane Schneider-Gold, MD, and Ralf Gold, MD, noted in JAMA Neurology that gefurulimab's position in the complement inhibitor landscape for generalized myasthenia gravis remains an open clinical question
  • ▪Three other C5 inhibitors previously approved by the FDA for myasthenia gravis are eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq)

Meningococcal infection warning

  • ▪Patients receiving FDA-approved C5 inhibitors for myasthenia gravis, including gefurulimab, are required to comply with recommendations for meningococcal vaccinations
  • ▪Gefurulimab carries a boxed warning for serious and life-threatening infections caused by Neisseria meningitidis, a warning shared by all approved FDA C5 inhibitors for myasthenia gravis

REMS program requirements

  • ▪The REMS program requirement for gefurulimab ensures safety protocols are enforced to manage the severe risks detailed in the drug's boxed warning
  • ▪Gefurulimab (Klygefa) is available to patients in the United States only through a Risk Evaluation and Mitigation Strategy (REMS) program

2 sources

MedPage Today
Injectable Nanobody Wins FDA Approval for Myasthenia Gravis
View source article
Endpoints
AstraZeneca, Alexion's mysathenia gravis treatment enters crowded market
View source article

Story comments

Loading comments…

Related entities

United StatesNeisseria meningitidisMyasthenia gravis

Related Projects

AstraZenecaEuropean Medicines Agency

Topics

Neurological disordersEuropean UnionClinical trialsAutoimmune disease treatmentsRandomized controlled trialRisk evaluation & mitigation (REMS)FDA drug approvalDrug safetyDrug Policy, Pricing & Approval